+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi



Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi



Cell and Tissue Research 351(1): 85-98



Perturbations in microRNA (miRNA) expression profiles have been reported for cutaneous malignant melanoma (CMM) predominantly when examined in cell lines. Despite the rapidly growing number of newly discovered human miRNA sequences, the availability of up-to-date miRNA expression profiles for clinical samples of primary cutaneous malignant melanoma (PCMM), cutaneous malignant melanoma metastases (CMMM), and benign melanocytic nevi (BMN) is limited. Specimens excised from the center of tumors (lesional) from patients with PCMM (n=9), CMMM (n=4), or BMN (n=8) were obtained during surgery. An exploratory microarray analysis was performed by miRNA expression profiling based on Agilent platform screening for 1205 human miRNAs. The results from the microarray analysis were validated by TaqMan quantitative real-time polymerase chain reaction. In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p, hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260, hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated. The results of this study partially confirm previous CMM miRNA profiling studies identifying miRNAs that are dysregulated in CMM. However, we report several novel miRNA candidates in CMM tumors; these miRNA sequences require further validation and functional analysis to evaluate whether they play a role in the pathogenesis of CMM.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036639067

Download citation: RISBibTeXText

PMID: 23111773

DOI: 10.1007/s00441-012-1514-5


Related references

The miRNA machinery in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases and benign melanocytic nevi. Cell and Tissue Research 350(1): 119-126, 2012

Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. American Journal of Surgical Pathology 22(8): 976-982, 1998

Bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. American Journal of Dermatopathology 17(1): 7, 1995

Fas and Fas ligand expression in benign melanocytic nevi and cutaneous malignant melanoma. Journal of Investigative Dermatology 108(4): 650, 1997

Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi. European Journal of Dermatology 21(1): 18-21, 2011

Expression of NM23 protein in acquired melanocytic nevi, malignant melanoma and metastases of malignant melanoma: an immunohistological assessment in human skin. Dermatology 194(2): 136-139, 1997

Impact of E-cadherin expression pattern in melanocytic nevi and cutaneous malignant melanoma. Analytical and Quantitative Cytopathology and Histopathology 34(4): 204-213, 2012

Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Laboratory Investigation; A Journal of Technical Methods and Pathology 67(3): 331-337, 1992

Skin lesions in melanoma and Kaposi's sarcoma. Case 2. Dermoscopic features of metastases from cutaneous melanoma mimicking benign nevi and primary melanoma. Journal of Clinical Oncology 20(5): 1412-1415, 2002

Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases. Journal of the American Academy of Dermatology 58(5): 750-754, 2008

Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Modern Pathology 19(2): 246-254, 2006

Expression of the DNA-mismatch repair enzyme hMSH2 in acquired melanocytic nevi, malignant melanoma and metastases of malignant melanoma and implications for its contribution to the repair of UV-induced DNA damage in melanocytes. Archives of Dermatological Research 295(8-9): 381, 2004

Increased Intraepidermal Melanocyte Frequency and Size in Dysplastic Melanocytic Nevi and Cutaneous Melanoma. A Comparative Quantitative Study of Dysplastic Melanocytic Nevi, Superficial Spreading Melanoma, Nevocellular Nevi, and Solar Lentigines. Journal of Investigative Dermatology 80(5): 452-459, 1983

Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi, and cutaneous malignant melanomas. American Journal of Dermatopathology 23(4): 308-314, 2001

Increased intra epidermal melanocyte frequency and size in dysplastic melanocytic nevi and cutaneous melanoma a comparative quantitative study of dysplastic melanocytic nevi superficial spreading melanoma nevo cellular nevi and solar lentigines. Journal of Investigative Dermatology 80(5): 452-459, 1983